The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
COMMENTARY
Diabetes Market Regaining Momentum with New Launches; First Oral GLP-1 a Game Changer?
The diabetes drug market is heating up again. Novo Nordisk Pharma’s Rybelsus (semaglutide), the first oral GLP-1 receptor agonist in Japan, was approved on June 29, while a number of insulin combination products and biosimilars have been launched as well.…
To read the full story
Related Article
- Chugai, Sanofi Wind Up License Deal for Apleway; Kowa to Get MA
February 18, 2020
- MSD to Transfer Japan Distribution Rights for DPP-4 Inhibitor Marizev to Kissei
February 4, 2020
- Novo Joins Hands with MSD in Oral Semaglutide Promotion
December 10, 2019
- Sumitomo Dainippon to Solely Promote Novartis Diabetes Meds from January
November 20, 2019
- Taisho, Novartis to Stop Comarketing Lusefi at December-End
October 31, 2019
COMMENTARY
- Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise
December 22, 2025
- FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed
December 9, 2025
- MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
November 17, 2025
- Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025
- The Price of Stability: Who Bears Japan’s Drug Distribution Burden?
October 27, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…